Genomics Reporting Implementation Guide
3.0.1-SNAPSHOT - Ballot International flag

Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.1-SNAPSHOT built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

: genomicstudy-trio2 - XML Representation

Raw xml | Download



<Procedure xmlns="http://hl7.org/fhir">
  <id value="genomicstudy-trio2"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study"/>
  </meta>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Procedure genomicstudy-trio2</b></p><a name="genomicstudy-trio2"> </a><a name="hcgenomicstudy-trio2"> </a><a name="hcgenomicstudy-trio2-en-US"> </a><p><b>identifier</b>: <code>http://www.somesystemabc.net/identifiers/genomicstudies</code>/urn:uuid:1111-1111-1111-1113 (use: temp, )</p><p><b>status</b>: Completed</p><p><b>category</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/observation-category laboratory}">Laboratory</span></p><p><b>code</b>: <span title="Codes:">Trio Analysis</span></p><p><b>subject</b>: <a href="Patient-denovoChild.html">Child Denovo (official) (no stated gender), DoB Unknown ( Medical record number: 1234-11111 (use: temp, ))</a></p><p><b>performed</b>: 2023-10-01</p><p><b>asserter</b>: <a href="Practitioner-practitioner02.html">Practitioner Jane Doel </a></p><p><b>note</b>: De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic.</p></div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study-analysis-ext">
    <valueReference>🔗 
      <reference value="Procedure/genomicstudyanalysis-trio2"/>
    </valueReference>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/genomic-study-referrer-ext">
    <valueReference>🔗 
      <reference value="Practitioner/practitioner02"/>
    </valueReference>
  </extension>
  <identifier>
    <use value="temp"/>
    <system value="http://www.somesystemabc.net/identifiers/genomicstudies"/>
    <value value="urn:uuid:1111-1111-1111-1113"/>
  </identifier>
  <status value="completed"/>
  <category>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/observation-category"/>
      <code value="laboratory"/>
    </coding>
  </category>
  <code>
    <text value="Trio Analysis"/>
  </code>
  <subject>🔗 
    <reference value="Patient/denovoChild"/>
  </subject>
  <performedDateTime value="2023-10-01"/>
  <asserter>🔗 
    <reference value="Practitioner/practitioner02"/>
  </asserter>
  <note>
    <text
          value="De novo mutation study of the patient. The Prenatal Trio Whole Exome Sequencing (Prenatal Trio WES) test is ordered by a physician and must be accompanied with a consent form and detailed clinical information. In general, the test is used when prenatal imaging detects an anomaly that strongly suggests that there is an underlying genetic etiology. Prenatal Trio WES is often considered only after fetal chromosome microarray analysis has been non-diagnostic."/>
  </note>
</Procedure>